Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.
Archive | Clinical Trials
BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
CheckMate-915 Trial Does Not Meet Co-Primary End Point of RFS for Melanoma
Updated results from the randomized, phase 3 CheckMate-915 trial found that nivolumab (Opdivo) plus ipilimumab (Yervoy) did not result in a statistically significant improvement in recurrence-free survival (RFS) in the intention-to-treat population of participants, according to Bristol Myers Squibb, the developer of the agents.
Posted in Melanoma News, Health Professionals, Clinical Trials
Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma
Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the rationale for the ?phase 3 CheckMate-067 trial in advanced melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
Five-Year Outcomes: First-Line Nivolumab vs Dacarbazine in Advanced BRAF Wild-Type Melanoma
The 5-year outcomes of the CheckMate 066 trial, reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, and colleagues, showed continued benefit of first-line nivolumab vs dacarbazine in advanced BRAF wild-type melanoma. The results add to data indicating that nivolumab can be associated with long-term survival in this setting.
Posted in Melanoma News, Health Professionals, Clinical Trials
